文献速递类风湿关节炎

接受乌帕替尼治疗的类风湿关节炎患者对13价肺炎球菌结合疫苗应答的评估:一项2期开放标签扩展研究的结果

Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study.
PubMed 文献 · RMD Open · 2022-01-01

基于2期开放标签扩展试验BALANCE-EXTEND,评估接受乌帕替尼15 mg或30 mg每日一次联合背景甲氨蝶呤的类风湿关节炎患者接种13价肺炎球菌结合疫苗(PCV-13)后的免疫原性。接种后4周,15 mg组67.5%(95%CI 57.4至77.5)和30 mg组56.5%(95%CI 36.3至76.8)的患者达到满意体液应答;是否联用糖皮质激素的患者应答相似;未报告死亡或严重不良事件。

要点

  • 15 mg组67.5%、30 mg组56.5%的患者在接种PCV-13后4周达到满意体液应答。
  • 联用与未联用糖皮质激素的患者PCV-13应答相似。
  • 未报告死亡或严重不良事件。

核心结论

  • 约三分之二接受乌帕替尼15 mg每日一次的患者尽管联用甲氨蝶呤,仍对PCV-13达到满意体液应答。
  • 联用糖皮质激素未对PCV-13应答产生负面影响。

研究设计与样本

  • 2期开放标签扩展试验BALANCE-EXTEND(NCT02049138),纳入接受稳定剂量乌帕替尼15 mg或30 mg每日一次联合背景甲氨蝶呤的合格患者,接种PCV-13。
  • 共111例患者(乌帕替尼15 mg组87例,30 mg组24例),接种前及接种后4周和12周采集抗体滴度。
  • 主要终点为接种后4周对12种肺炎球菌抗原中至少6种抗体滴度升高至少2倍的患者比例(满意体液应答)。

主要发现

  • 111例患者中85.6%为女性,97.3%联用甲氨蝶呤,44.1%使用口服糖皮质激素。
  • 接种后4周,乌帕替尼15 mg组67.5%(95%CI 57.4至77.5)和30 mg组56.5%(95%CI 36.3至76.8)的患者达到满意PCV-13应答。
  • 联用与未联用糖皮质激素的患者应答相似。
  • 未报告死亡或严重不良事件。

关键数值与推荐

  • 满意体液应答定义为接种后4周对12种肺炎球菌抗原中至少6种抗体滴度升高至少2倍。
  • 乌帕替尼15 mg组满意应答比例67.5%(95%CI 57.4至77.5),30 mg组56.5%(95%CI 36.3至76.8)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the immunogenicity of pneumococcal 13-valent conjugate vaccination (PCV-13) in patients with rheumatoid arthritis receiving upadacitinib and background methotrexate (MTX). METHODS: Eligible patients from the phase 2 open-label extension trial BALANCE-EXTEND (NCT02049138) receiving stable dosing of upadacitinib 15 mg or 30 mg once daily plus background MTX were given PCV-13. Antibody titres were collected prevaccination and 4 and 12 weeks postvaccination. The primary endpoint was the proportion of patients with satisfactory humoral response to PCV-13, defined as a ≥2-fold increase in ≥6 of 12 pneumococcal antigens at 4 weeks postvaccination. RESULTS: Of 111 patients (upadacitinib 15 mg, N=87; 30 mg, N=24), 85.6% were women, 97.3% used concomitant MTX and 44.1% used oral corticosteroids. At 4 weeks, 67.5% (95% CI 57.4 to 77.5) of patients receiving upadacitinib 15 mg and 56.5% (36.3 to 76.8) receiving 30 mg had a satisfactory PCV-13 response. Responses were similar in patients who used or did not use concomitant corticosteroids. No deaths or serious adverse events were reported. CONCLUSIONS: Approximately two-thirds of patients receiving upadacitinib 15 mg once daily achieved a satisfactory humoral response to PCV-13 despite receiving concomitant MTX. Concomitant corticosteroid use did not negatively affect PCV-13 response.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Winthrop K, Vargas JI, Drescher E, et al. Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study. RMD Open. 2022. PMID: 35246470. doi:10.1136/rmdopen-2021-002110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。